Comparative Pharmacology
Head-to-head clinical analysis: ARALEN PHOSPHATE W PRIMAQUINE PHOSPHATE versus FANSIDAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARALEN PHOSPHATE W PRIMAQUINE PHOSPHATE versus FANSIDAR.
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE vs FANSIDAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Fansidar combines sulfadoxine, a sulfonamide dihydrofolate reductase inhibitor, and pyrimethamine, a dihydrofolate reductase inhibitor, synergistically inhibiting folate synthesis in Plasmodium species, leading to nucleic acid synthesis inhibition and parasite death.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
For acute uncomplicated malaria: 3 tablets (25 mg pyrimethamine + 500 mg sulfadoxine per tablet) orally as a single dose on Day 0 and Day 1 (total 6 tablets); alternatively, 3 tablets as a single dose. For severe malaria: 3 tablets orally as a single dose, repeated at weekly intervals if necessary.
None Documented
None Documented
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Sulfadoxine: 100-200 hours; pyrimethamine: 80-100 hours; clinical context: unusual for antimalarials, allows single-dose therapy for uncomplicated P. falciparum
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
Renal: sulfadoxine 80% (unchanged), pyrimethamine 20-40% (unchanged); fecal: sulfadoxine <5%, pyrimethamine <5%
Category D/X
Category C
Antimalarial
Antimalarial